NCT05333861View on ClinicalTrials.gov

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Not yet recruitingOBSERVATIONAL

Enrollment

1,150

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions

Primary Immune ThrombocytopeniaAplastic Anemia

Interventions

DRUG

hetrombopag

According to prescription

Trial Locations (1)

430022

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT05333861 - An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA | Biotech Hunter | Biotech Hunter